[
    [
        {
            "time": "2021-03-17",
            "original_text": "贝达药业MCLA-129获批开展临床试验",
            "features": {
                "keywords": [
                    "贝达药业",
                    "MCLA-129",
                    "临床试验",
                    "实体瘤"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业MCLA-129获批开展临床试验",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-03-17",
            "original_text": "贝达药业引进的EGFR/c-Met双特异性抗体获得临床默示许可 | 医麦猛爆料",
            "features": {
                "keywords": [
                    "贝达药业",
                    "EGFR/c-Met",
                    "双特异性抗体",
                    "临床默示许可"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业引进的EGFR/c-Met双特异性抗体获得临床默示许可 | 医麦猛爆料",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-03-17",
            "original_text": "贝达药业：MCLA-129注射液获得临床试验批准通知书",
            "features": {
                "keywords": [
                    "贝达药业",
                    "MCLA-129",
                    "注射液",
                    "临床试验"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业：MCLA-129注射液获得临床试验批准通知书",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-03-17",
            "original_text": "贝达药业(300558.SZ)：MCLA-129注射液用于治疗晚期实体瘤获批临试",
            "features": {
                "keywords": [
                    "贝达药业",
                    "MCLA-129",
                    "晚期实体瘤",
                    "临床试验"
                ],
                "sentiment_score": 0.88,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：MCLA-129注射液用于治疗晚期实体瘤获批临试",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-03-17",
            "original_text": "贝达药业：药品临床试验申请获批准",
            "features": {
                "keywords": [
                    "贝达药业",
                    "临床试验",
                    "药品"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业：药品临床试验申请获批准",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-03-17",
            "original_text": "贝达药业治疗晚期实体瘤注射液获批临床试验",
            "features": {
                "keywords": [
                    "贝达药业",
                    "晚期实体瘤",
                    "注射液",
                    "临床试验"
                ],
                "sentiment_score": 0.87,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业治疗晚期实体瘤注射液获批临床试验",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]